Chad R. Lund
2329 West Mall
Vancouver, BC V6T1Z4, Canada
Vancouver, BC V6T1Z4, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications
Five-year follow-up of the SABR-5 trial: primary toxicity analysis of stereotactic ablative radiotherapy for up to five oligometastases.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: February 21, 2026
Evaluating Toxicity and Interaction Outcomes of Systemic Therapy and Stereotactic Ablative Radiation Therapy for Oligometastatic Disease: A Secondary Analysis of the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: October 16, 2024
Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: August 07, 2023
Should organs at risk (OARs) be prioritized over target volume coverage in stereotactic ablative radiotherapy (SABR) for oligometastases? a secondary analysis of the population-based phase II SABR-5 trial.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 09, 2022
A perspective on in person scientific meetings.
Journal: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Published: December 09, 2022
Treatment With Stereotactic Ablative Radiotherapy for Up to 5 Oligometastases in Patients With Cancer: Primary Toxic Effect Results of the Nonrandomized Phase 2 SABR-5 Clinical Trial.
Journal: JAMA oncology
Published: September 29, 2022
Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial.
Journal: International journal of radiation oncology, biology, physics
Published: March 10, 2022
Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy.
Journal: Current oncology (Toronto, Ont.)
Published: March 12, 2019
Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014.
Journal: Current oncology (Toronto, Ont.)
Published: April 25, 2015
The impact of peer review of volume delineation in stereotactic body radiation therapy planning for primary lung cancer: a multicenter quality assurance study.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: April 17, 2014
The Distribution and Patterns of Practice of Stereotactic Ablative Body Radiotherapy in Canada.
Journal: Journal of medical imaging and radiation sciences
Published: February 05, 2013
Showing 1-12 of 12
Last Updated: 09/26/2026